Shanghai Model Organisms Center Inc

Shanghai Model Organisms Center, Inc. is engaged in the research, development, production, sale, and related technical services of genetically modified animal models. The company uses model organisms such as mice, rats, zebrafish, and nematodes as carriers, applying gene editing technology to introduce or delete target DNA fragments. It offers a toolbox of mice, including disease models for rare, infectious, and nervous system diseases, cardio-metabolic, autoimmune, and spontaneous tumor models, as well as target humanized knock-ins covering tumor targets, immune checkpoints, complements, cytokines, and metabolic and other targets, along with cytokine reporters, inducible cell ablation, and cell-specific reporters. The company also provides other models including rats (humanized drug targets, immunodeficient, disease, reporter, and cre-driver models), standard strains (inbred and outbred), cell models (reporter-labeled, primary, wild-type, and others), and supporting solutions such as colony management (cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services) and auxiliary apparatuses like the e-BLOT WB imaging system. Additionally, it offers preclinical services including non-GLP toxicology, pharmacokinetics, phenotype analysis, and pharmacology and pharmacodynamics, and treatments for therapeutic areas such as oncology, nervous system, autoimmune, and digestive system diseases. The company was founded in 2000 and is headquartered in Shanghai, China.

Biotech & Genomic Medicine▼

Yakang Bio expects first-half net profit attributable to parent to rise 46.67% to 60.78%

Yakang Bio released its 2026 half-year performance forecast, projecting net profit attributable to the parent of 104 million yuan to 114 million yuan for the first half, a year-on-year increase of 46.67% to 60.78%. Net profit attributable to the parent after deducting non-recurring items is expected to be 92 million yuan to 100 million yuan, up 46.20% to 58.92%. Based on this, net profit attributable to the parent in the second quarter is estimated at roughly 56.8962 million yuan to 66.8962 million yuan, representing year-on-year growth of 39.02% to 63.46% and quarter-on-quarter growth of 20.79% to 42.02%. The company attributed the improved performance to recovering demand in both domestic and overseas markets. It has completed its layout in three core regions overseas: North America, Europe, and Asia-Pacific, with high-margin revenue maintaining rapid growth. Domestically, it benefited from a recovery in the biomedical industry and volume expansion in functional efficacy businesses. On the cost side, capacity utilization at newly built production bases increased, releasing economies of scale. Coupled with refined cost control, this drove an improvement in gross margin and a decline in period expense ratios. Yakang Bio is one of the three major model animal companies in China, primarily engaged in the sale of laboratory mouse models, with over 22,000 mouse strains. It is actively developing innovative models such as humanized mice. However, intensifying industry competition poses risks of product price pressure and limited growth potential.

688046.CG ▼688265.CG ▼

Biotech & Genomic Medicine ▲

科创板日报·59dRead more →